Four phases. One destination.
The Project Juvet development program advances from biological foundation to first pilot deployment across four overlapping phases. Each phase produces independently validated technical milestones that feed the next.
Biological Substrate Validation
Phase 1 establishes the biological foundation of the Project Juvet construct. The primary objective is the development and validation of a reproducible tri-layer bioprinted tissue construct incorporating quantum sensing materials and ChR2-expressing dermal fibroblasts. Every subsequent phase builds on the validated outputs of Phase 1.
Substrate architecture and biological performance
- Tri-layer GelMA-fibrin scaffold fabrication protocol established
- Ag2S quantum dot bioink formulation optimized for biological compatibility
- ChR2-expressing dermal fibroblast integration and transduction validated
- Cell viability benchmarks achieved: greater than 90% at day 7 post-printing
- Bioprinting protocol package completed and documented
Reproducible bioprinted tissue construct validated across multiple independent print runs meeting defined biological performance criteria. Foundation established for Phase 2 integration.
Quantum Sensing Integration
Phase 2 integrates the quantum sensing and photonic actuation elements into the Phase 1 construct. The objective is demonstrating functional optical readout from the quantum sensing layer and biological haptic activation through optogenetic cell response within the tissue construct architecture.
Functional sensing and haptic activation
- Ag2S NIR-II quantum dot signal fidelity validated at 1.4× beyond classical shot-noise limit
- Micro-ILED array fabricated on flexible substrate and integrated into construct
- Functional optical signal readout demonstrated from quantum sensing layer
- Biological haptic activation demonstrated through optogenetic cell response
- AI inference algorithm validated for neural signal classification
Integrated construct demonstrating functional optical signal readout and biological haptic activation. Cell viability maintained through integration process. Architecture validated for Phase 3 quantum channel integration.
Photonic Communication & AI Inference
Phase 3 integrates the quantum communication layer and the photonic AI inference chip into the construct, demonstrating the full bidirectional communication loop between two paired constructs. This is the most technically complex phase and establishes the quantum-secured channel and sub-milliwatt edge inference that are central to the Project Juvet architecture.
Bidirectional quantum channel and edge AI
- Quantum communication node integrated into Phase 2 construct
- Entangled photon pair source miniaturized and embedded in construct architecture
- QKD-secured bidirectional channel validated at 92% fidelity between paired constructs
- Sub-milliwatt photonic AI inference validated at under 5ms classification latency
- Regulatory pre-submission work initiated with FDA
Quantum-secured bidirectional communication demonstrated between two paired constructs at defined operational range and fidelity targets. Photonic AI inference operational. FDA pre-submission pathway initiated.
Full System Integration
Phase 4 assembles the complete paired construct system for the first time, producing the first full Project Juvet prototype suitable for controlled pilot deployment and IRB-reviewed human factors studies. This phase also advances the formal FDA regulatory process and files the non-provisional patent applications.
Operational prototype and pilot deployment
- Commercial-specification AI inference chip integrated into complete system
- Complete paired construct system assembled and validated end-to-end
- Closed-loop bidirectional operation verified below 10ms end-to-end latency
- First pilot deployment in controlled laboratory setting with IRB approval
- FDA regulatory pathway established via pre-submission meeting
- Non-provisional patent applications filed across 5 patent families
Complete operational Project Juvet prototype demonstrating all four integrated layers in a continuous bidirectional loop. First pilot deployment documented. FDA regulatory pathway confirmed. IP portfolio secured for international prosecution.
From laboratory to first pilot. 48 months.
Ready to learn more? Request the full briefing.
Detailed technical roadmap, development milestones, operating budget model, and financial projections available to accredited investors under NDA.